Organogenesis (ORGO)
(Delayed Data from NSDQ)
$3.25 USD
+0.05 (1.56%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.25 USD
+0.05 (1.56%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
Zacks News
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -550% and 6.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 31.03% and 18.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
by Zacks Equity Research
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for January 5th
by Zacks Equity Research
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
New Strong Buy Stocks for January 5th
by Zacks Equity Research
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra
by Zacks Equity Research
Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra are included in this Analyst Blog.
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
by Sanghamitra Saha
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)
by Zacks Equity Research
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?
by Zacks Equity Research
Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -15.69% and 1.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Organogenesis (ORGO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Abbott (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.